

Special Issue

Rabies Vaccination and Immunotherapy

Message from the Guest Editor

Although rabies virus is nearly 100% fatal once clinical signs develop, it is also a vaccine-preventable disease. However, multiple factors have impeded successful and widespread administration of rabies vaccines and immunotherapies, including expense and the need for cold chain storage in areas that are remote and may lack reliable electricity. Additionally, vaccines and immunotherapies for rabies virus need to demonstrate high efficacy given the potential for a fatal outcome in untreated or inadequately treated individuals exposed to rabies virus. The goal of this Special Issue is to feature manuscripts addressing the advancements in the treatment and prevention of rabies infection, including but not limited to developing effective rabies vaccines, novel therapeutics, antiviral response, animal models, and delivery methods. Research articles that describe prevention and potential treatment for lyssavirus phylogroups II and III are also welcome.

Guest Editor

Dr. April D. Davis

The Laboratory of Immunology, The Wadsworth Center, New York State Department of Health, Albany, NY 12201-2002, USA

Deadline for manuscript submissions

closed (20 August 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/64288

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).